2022 Genitourinary Cancers Symposium | Supplements and Featured Publications

March 10, 2022

Rana R. McKay, MD, discusses findings from a real-world study on genomic alterations of metastases in renal cell carcinoma, the rationale of the phase 3 COSMIC-313 trial in patients with previously untreated advanced or metastatic RCC, plus findings from the phase 1/2 COMRADE trial in patients with metastatic castration-resistant prostate cancer.

March 02, 2022

Moshe Ornstein, MD, MA, discusses trials exploring second-line immunotherapy in patients who have progressed on immunotherapy, plus key clinical trial data on kidney cancer and other pressing areas of need for research in renal cell carcinoma.

February 25, 2022

The FDA approvals of immunotherapy-based combinations as frontline therapy led to a substantial increase in their use in patients with metastatic renal cell carcinoma in the community setting, leading to a greater use of TKI monotherapy as second- and third-line therapies.

February 19, 2022

The addition of olaparib to durvalumab did not result in a significant prolongation in progression-free survival compared with durvalumab alone in patients with previously untreated, platinum-ineligible metastatic urothelial carcinoma.

February 18, 2022

The utilization of 18F-rhPSMA-7.3 imaging displayed a clinically meaningful correct detection rate.

February 18, 2022

The androgen receptor inhibitor darolutamide demonstrated continued efficacy and safety in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who have comorbidities or concomitant medications